NPORT-EX 2 NPORT_8695146031271991.htm iShares Evolved US Innovative Healthcare ETF

Schedule of Investments  (unaudited)

April 30, 2020

   

iShares® Evolved U.S. Innovative Healthcare ETF

(Percentages shown are based on Net Assets)

 

Security   Shares     Value  

Common Stocks

 

Biotechnology — 40.9%  

Abeona Therapeutics Inc.(a)

    306     $ 728  

ACADIA Pharmaceuticals Inc.(a)

    1,242       60,001  

Acceleron Pharma Inc.(a)

    423       38,294  

Achillion Pharmaceuticals Inc.(a)(b)(c)

    624       287  

Acorda Therapeutics Inc.(a)

    459       442  

Aduro Biotech Inc.(a)

    414       1,145  

Adverum Biotechnologies Inc.(a)

    683       8,094  

Agenus Inc.(a)

    783       2,087  

Alder Biopharmaceuticals Inc.(a)(b)

    312       275  

Alexion Pharmaceuticals Inc.(a)

    2,113          227,084  

Allakos Inc.(a)(c)

    305       20,057  

Allogene Therapeutics Inc.(a)

    430       12,427  

Alnylam Pharmaceuticals Inc.(a)(c)

    1,323       174,239  

AMAG Pharmaceuticals Inc.(a)

    288       2,313  

Amgen Inc.

     2,484       594,222  

Amicus Therapeutics Inc.(a)(c)

    2,482       29,312  

AnaptysBio Inc.(a)

    153       2,390  

ANI Pharmaceuticals Inc.(a)

    63       2,521  

Apellis Pharmaceuticals Inc.(a)

    556       19,054  

Ardelyx Inc.(a)

    773       5,086  

Arena Pharmaceuticals Inc.(a)

    576       28,207  

Arrowhead Pharmaceuticals Inc.(a)

    1,186       40,834  

Assembly Biosciences Inc.(a)

    198       3,467  

Atara Biotherapeutics Inc.(a)

    288       2,387  

Avrobio Inc.(a)

    271       3,488  

BioCryst Pharmaceuticals Inc.(a)

    963       3,765  

Biogen Inc.(a)

    1,773       526,280  

Biohaven Pharmaceutical Holding Co. Ltd.(a)

    322       15,166  

BioMarin Pharmaceutical Inc.(a)

    1,978       182,016  

Bio-Rad Laboratories Inc., Class A(a)

    18       7,922  

Bluebird Bio Inc.(a)(c)

    431       23,222  

Blueprint Medicines Corp.(a)

    505       29,709  

Bridgebio Pharma Inc.(a)(c)

    235       7,175  

Cara Therapeutics Inc.(a)

    324       4,802  

Celldex Therapeutics Inc.(a)

    44       108  

ChemoCentryx Inc.(a)

    467       24,756  

Constellation Pharmaceuticals Inc.(a)

    251       9,031  

Cymabay Therapeutics Inc.(a)

    719       1,273  

CytomX Therapeutics Inc.(a)

    351       3,622  

Deciphera Pharmaceuticals Inc.(a)

    316       18,322  

Denali Therapeutics Inc.(a)

    774       16,920  

Dicerna Pharmaceuticals Inc.(a)

    619       12,194  

Dynavax Technologies Corp.(a)

    576       2,448  

Editas Medicine Inc.(a)

    432       9,988  

Emergent BioSolutions Inc.(a)

    288       21,298  

Epizyme Inc.(a)

    854       14,057  

Esperion Therapeutics Inc.(a)

    279       11,048  

Exact Sciences Corp.(a)

    457       36,094  

Exelixis Inc.(a)

    2,898       71,566  

Fate Therapeutics Inc.(a)

    495       13,553  

FibroGen Inc.(a)

    828       30,545  

Five Prime Therapeutics Inc.(a)

    405       1,328  

Geron Corp.(a)(c)

    1,107       1,317  

Gilead Sciences Inc.

     8,299       697,116  

GlycoMimetics Inc.(a)

    415       1,158  

Gossamer Bio Inc.(a)(c)

    576       7,499  

Guardant Health Inc.(a)

    205       15,777  

Halozyme Therapeutics Inc.(a)

    1,080       24,467  
Security   Shares     Value  
Biotechnology (continued)  

ImmunoGen Inc.(a)

    1,708     $ 6,969  

Immunomedics Inc.(a)

    1,809       54,957  

Incyte Corp.(a)

    898       87,699  

Innoviva Inc.(a)

    531       7,530  

Insmed Inc.(a)

    810       18,630  

Intercept Pharmaceuticals Inc.(a)

    305       24,986  

Ionis Pharmaceuticals Inc.(a)

    1,394       77,409  

Iovance Biotherapeutics Inc.(a)

    1,143       36,747  

Karuna Therapeutics Inc.(a)

    117       9,720  

Karyopharm Therapeutics Inc.(a)(c)

    504       11,113  

Krystal Biotech Inc.(a)

    124       5,852  

Lexicon Pharmaceuticals Inc.(a)(c)

    477       902  

Ligand Pharmaceuticals Inc.(a)

    216       21,291  

MacroGenics Inc.(a)

    360       2,592  

Mirati Therapeutics Inc.(a)

    350       29,764  

Moderna Inc.(a)

    2,278       104,765  

Myriad Genetics Inc.(a)

    315       4,870  

Nektar Therapeutics(a)

    1,756       33,715  

NextCure Inc.(a)

    151       4,895  

Novavax Inc.(a)

    144       2,611  

Omeros Corp.(a)

    423       7,030  

Pieris Pharmaceuticals Inc.(a)

    576       1,526  

PRECIGEN Inc.(a)(c)

    396       1,426  

Prothena Corp. PLC(a)

    394       4,421  

PTC Therapeutics Inc.(a)

    585       29,788  

Puma Biotechnology Inc.(a)

    351       3,528  

Radius Health Inc.(a)

    450       7,060  

Regeneron Pharmaceuticals Inc.(a)

    862       453,309  

REGENXBIO Inc.(a)

    306       12,185  

Retrophin Inc.(a)

    423       6,438  

Rigel Pharmaceuticals Inc.(a)

    1,611       2,884  

Rocket Pharmaceuticals Inc.(a)(c)

    235       3,478  

Rubius Therapeutics Inc.(a)

    368       2,226  

Sage Therapeutics Inc.(a)

    657       25,610  

Sangamo Therapeutics Inc.(a)

    1,422       11,589  

Seattle Genetics Inc.(a)

    1,269       174,145  

Solid Biosciences Inc.(a)

    145       336  

Sorrento Therapeutics Inc.(a)(c)

    621       1,410  

Stemline Therapeutics Inc.(a)

    333       1,742  

Theravance Biopharma Inc.(a)(c)

    439       12,801  

Turning Point Therapeutics Inc.(a)

    298       15,350  

Ultragenyx Pharmaceutical Inc.(a)

    504       30,457  

United Therapeutics Corp.(a)

    423       46,344  

Vericel Corp.(a)(c)

    215       3,117  

Vertex Pharmaceuticals Inc.(a)

    2,656       667,187  

Viking Therapeutics Inc.(a)

    583       3,358  

WaVe Life Sciences Ltd.(a)(c)

    189       1,640  

Xencor Inc.(a)

    540       15,784  

Y-mAbs Therapeutics Inc.(a)

    261       8,764  

ZIOPHARM Oncology Inc.(a)

    1,368       3,830  
   

 

 

  
        5,229,763  
Chemicals — 0.0%            

Codexis Inc.(a)

    406       4,714  
   

 

 

  
Electrical Components & Equipment — 0.2%            

Universal Display Corp.(c)

    126       18,915  
   

 

 

  
Health Care – Products — 3.7%            

Abbott Laboratories

     622       57,280  

ABIOMED Inc.(a)

    43       8,224  
 

 

 

1

Schedule of Investments  (unaudited) (continued)

April 30, 2020

   

iShares® Evolved U.S. Innovative Healthcare ETF

(Percentages shown are based on Net Assets)

 

Security   Shares     Value  
Health Care – Products (continued)            

Axogen Inc.(a)

    126     $ 1,228  

Baxter International Inc.

     1,044       92,686  

Cooper Companies Inc. (The)

     144       41,285  

Glaukos Corp.(a)

    234       8,585  

Haemonetics Corp.(a)

    117       13,312  

Hologic Inc.(a)

    324       16,232  

ICU Medical Inc.(a)

    45       9,869  

IDEXX Laboratories Inc.(a)

    90       24,984  

Insulet Corp.(a)

    134       26,762  

Integra LifeSciences Holdings Corp.(a)

    153       7,811  

Intersect ENT Inc.(a)

    162       1,860  

Intuitive Surgical Inc.(a)

    52       26,566  

Lantheus Holdings Inc.(a)

    252       3,289  

Merit Medical Systems Inc.(a)

    117       4,776  

Natera Inc.(a)

    171       6,334  

Nevro Corp.(a)

    126       14,823  

Novocure Ltd.(a)

    495       32,571  

Penumbra Inc.(a)

    46       8,157  

Precision BioSciences Inc.(a)

    431       2,965  

Repligen Corp.(a)

    198       22,998  

ResMed Inc.

     244       37,898  

Wright Medical Group NV(a)

    277       8,066  
   

 

 

  
         478,561  
Health Care – Services — 1.2%            

Catalent Inc.(a)

    468       32,362  

Charles River Laboratories International Inc.(a)

    162       23,437  

IQVIA Holdings Inc.(a)

    468       66,732  

Medpace Holdings Inc.(a)

    89       7,108  

OPKO Health Inc.(a)(c)

    2,061       4,575  

Syneos Health Inc.(a)

    252       14,059  
   

 

 

  
      148,273  
Pharmaceuticals — 51.3%            

AbbVie Inc.

     6,724       552,713  

Aclaris Therapeutics Inc.(a)

    306       407  

Adamas Pharmaceuticals Inc.(a)(c)

    207       669  

Aerie Pharmaceuticals Inc.(a)

    405       6,172  

Agios Pharmaceuticals Inc.(a)

    621       25,548  

Aimmune Therapeutics Inc.(a)

    432       7,396  

Akcea Therapeutics Inc.(a)

    117       1,996  

Akebia Therapeutics Inc.(a)

    864       6,998  

Akorn Inc.(a)(c)

    468       98  

Alector Inc.(a)

    314       7,762  

Alkermes PLC(a)

    1,513       20,743  

Allergan PLC

     2,116       396,411  

AmerisourceBergen Corp.

     126       11,297  

Amneal Pharmaceuticals Inc.(a)

    1,207       4,381  

Amphastar Pharmaceuticals Inc.(a)

    297       5,034  

Anika Therapeutics Inc.(a)

    90       2,991  

Antares Pharma Inc.(a)

    1,332       4,316  

Arvinas Holding Co. LLC(a)

    232       12,180  

Athenex Inc.(a)(c)

    730       6,526  

Axsome Therapeutics Inc.(a)

    205       19,481  

Bausch Health Companies Inc.(a)(c)

    1,998       36,204  

Bristol-Myers Squibb Co.

     10,871       661,066  

Catalyst Pharmaceuticals Inc.(a)(c)

    676       3,204  

Clovis Oncology Inc.(a)(c)

    522       3,972  

Coherus Biosciences Inc.(a)

    692       11,487  

Collegium Pharmaceutical Inc.(a)

    243       5,025  

Concert Pharmaceuticals Inc.(a)(c)

    216       2,156  
Security   Shares     Value  
Pharmaceuticals (continued)            

Corbus Pharmaceuticals Holdings Inc.(a)

    504     $ 3,266  

Corcept Therapeutics Inc.(a)

    990       12,533  

Cyclerion Therapeutics Inc.(a)

    135       522  

Cytokinetics Inc.(a)

    486       7,343  

DexCom Inc.(a)

    268       89,834  

Eagle Pharmaceuticals Inc./DE(a)

    126       6,424  

Elanco Animal Health Inc.(a)

    1,594       39,388  

Eli Lilly & Co.

     4,663       721,086  

Enanta Pharmaceuticals Inc.(a)

    153       7,095  

Endo International PLC(a)

    1,414       6,504  

Flexion Therapeutics Inc.(a)

    351       3,735  

G1 Therapeutics Inc.(a)

    198       2,600  

Global Blood Therapeutics Inc.(a)(c)

    676       51,728  

Heron Therapeutics Inc.(a)(c)

    738       10,524  

Horizon Therapeutics PLC(a)

    1,654       59,610  

Intellia Therapeutics Inc.(a)(c)

    306       4,122  

Intra-Cellular Therapies Inc.(a)(c)

    468       8,270  

Ironwood Pharmaceuticals Inc.(a)

    1,350       13,500  

Jazz Pharmaceuticals PLC(a)

    505       55,676  

Johnson & Johnson

     8,073         1,211,273  

Jounce Therapeutics Inc.(a)

    162       794  

Kadmon Holdings Inc.(a)

    2,005       8,622  

Kodiak Sciences Inc.(a)(c)

    306       16,692  

Kura Oncology Inc.(a)

    333       4,845  

La Jolla Pharmaceutical Co.(a)

    207       1,503  

Lannett Co. Inc.(a)

    261       2,490  

Madrigal Pharmaceuticals Inc.(a)

    88       7,364  

Mallinckrodt PLC(a)(c)

    394       1,600  

MediciNova Inc.(a)

    369       1,900  

Merck & Co. Inc.

     10,492       832,435  

Momenta Pharmaceuticals Inc.(a)

    1,225       38,833  

Mylan NV(a)

    3,501       58,712  

MyoKardia Inc.(a)

    466       29,274  

Neurocrine Biosciences Inc.(a)

    1,080       105,991  

Odonate Therapeutics Inc.(a)

    144       4,054  

Pacira BioSciences Inc.(a)

    342       14,121  

Paratek Pharmaceuticals Inc.(a)

    279       1,141  

Perrigo Co. PLC

     567       30,221  

Pfizer Inc.

     19,070       731,525  

Portola Pharmaceuticals Inc.(a)

    801       5,671  

PRA Health Sciences Inc.(a)

    189       18,239  

Prestige Consumer Healthcare Inc.(a)

    144       5,859  

Principia Biopharma Inc.(a)(c)

    244       15,172  

Progenics Pharmaceuticals Inc.(a)

    693       2,730  

Reata Pharmaceuticals Inc., Class A(a)(c)

    280       44,285  

Relmada Therapeutics Inc.(a)

    144       6,042  

Revance Therapeutics Inc.(a)

    324       5,997  

Rhythm Pharmaceuticals Inc.(a)

    394       7,423  

Sarepta Therapeutics Inc.(a)

    754       88,882  

Spectrum Pharmaceuticals Inc.(a)

    1,053       3,054  

Supernus Pharmaceuticals Inc.(a)

    495       11,583  

Synergy Pharmaceuticals Inc.(a)(c)

    1,136       7  

TG Therapeutics Inc.(a)

    531       6,245  

TherapeuticsMD Inc.(a)(c)

    1,440       2,275  

Tricida Inc.(a)

    288       8,712  

UroGen Pharma Ltd.(a)

    145       3,220  

Vanda Pharmaceuticals Inc.(a)

    504       5,796  

Voyager Therapeutics Inc.(a)

    288       3,113  

Zoetis Inc.

     2,107       272,456  

Zogenix Inc.(a)

    448       12,647  
   

 

 

  
      6,552,791  
 

 

 

2

Schedule of Investments  (unaudited) (continued)

April 30, 2020

   

iShares® Evolved U.S. Innovative Healthcare ETF

(Percentages shown are based on Net Assets)

 

Security   Shares     Value  
Telecommunications — 0.0%            

InterDigital Inc.

     81     $ 4,679  
   

 

 

  

Total Common Stocks — 97.3%
(Cost: $11,682,548)

       12,437,696  
   

 

 

  
Rights            
Pharmaceuticals — 0.1%            

Bristol-Myers Squibb Co. (Expires 3/31/2021)(a)

    2,353       10,612  
   

 

 

  

Total Rights — 0.1%
(Cost: $5,012)

       10,612  
   

 

 

  

Short-Term Investments

 

Money Market Funds — 5.1%  

BlackRock Cash Funds: Institutional,
SL Agency Shares,
    0.89%(d)(e)(f)

    324,982       325,340  
Security   Shares     Value  
Money Market Funds (continued)            

BlackRock Cash Funds: Treasury,
SL Agency Shares,
    0.18%(d)(e)

    322,000     $ 322,000  
   

 

 

  
      647,340  
   

 

 

  

Total Short-Term Investments — 5.1%
(Cost: $647,076)

       647,340  
   

 

 

  

Total Investments in Securities — 102.5%
(Cost: $12,334,636)

       13,095,648  

Other Assets, Less Liabilities — (2.5)%

       (316,300 ) 
   

 

 

  

Net Assets — 100.0%

     $ 12,779,348  
   

 

 

  

 

(a) 

Non-income producing security.

(b) 

Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.

(c) 

All or a portion of this security is on loan.

(d) 

Affiliate of the Fund.

(e) 

Annualized 7-day yield as of period-end.

(f) 

All or a portion of this security was purchased with cash collateral received from loaned securities.

 

 

Affiliates

Investments in issuers considered to be affiliates of the Fund during the nine months ended April 30, 2020, for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

 

 

  
Affiliated Issuer    Shares
Held at
07/31/19		      Net Activity      Shares
Held at
04/30/20		      Value at
04/30/20		      Income      Net Realized
Gain (Loss)(a)		     

Change in
Unrealized
Appreciation

(Depreciation)

  

 

  

BlackRock Cash Funds: Institutional,
SL Agency Shares

      187,167        137,815        324,982      $ 325,340      $ 1,472 (b)     $ (49 )     $ 219  

BlackRock Cash Funds: Treasury,
SL Agency Shares

      73,000        249,000        322,000        322,000        838        —        —  
           

 

 

     

 

 

     

 

 

     

 

 

  
            $ 647,340      $ 2,310      $ (49 )     $ 219  
           

 

 

     

 

 

     

 

 

     

 

 

  

 

  (a) 

Includes realized capital gain distributions from an affiliated fund, if any.

 
  (b) 

Includes securities lending income earned from the reinvestment of cash collateral from loaned securities (excluding collateral investment fees), net of fees and other payments to and from borrowers of securities, and less fees paid to BTC as securities lending agent.

 

Fair Value Measurements

Various inputs are used in determining the fair value of financial instruments. For description of the input levels and information about the Fund’s policy regarding valuation of financial instruments, refer to a recently published shareholder report. Shareholder reports are available on the Fund’s website at iShares.com and on the U.S. Securities and Exchange Commission website at sec.gov.

The following table summarizes the value of the Fund’s investments according to the fair value hierarchy as of April 30, 2020. The breakdown of the Fund’s investments into major categories is disclosed in the Schedule of Investments above.

 

                                                                   

 

  
     Level 1        Level 2        Level 3        Total  

 

  

Investments

                  

Assets

                  

Common Stocks

    $ 12,437,134        $ —        $ 562        $ 12,437,696  

Rights

      10,612          —          —          10,612  

Money Market Funds

      647,340          —          —          647,340  
  

 

 

       

 

 

       

 

 

       

 

 

  
   $ 13,095,086        $             —        $ 562        $ 13,095,648  
  

 

 

       

 

 

       

 

 

       

 

 

  

 

 

          3